Nicolas Gendron: Everolimus and Venous Thromboembolic Risk in Kidney Transplantation
Nicolas Gendron, Postdoctorate research Fellow at Harvard Medical School, Research Fellow and Hematologist at Boston Children’s Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Everolimus and venous thromboembolic risk in kidney transplantation
We are pleased to share with Lina Khider the results of our retrospective observational study, combining a case series and an analysis of the French National Pharmacovigilance Database.
Everolimus, a selective mTOR inhibitor widely used in transplantation, has already been associated with an increased risk of MVTE in heart and lung transplant recipients. Its impact on kidney transplant patients remained poorly documented.
Our main results:
In our center: 5 kidney transplant patients on everolimus presented with MVTE, including 3 recurrences. Median time to onset: 11 months after initiation.
16 additional cases identified via national pharmacovigilance, all organs combined (heart 43.8percent, lung 18.8percent, kidney 18.8percent)
The risk appears to be particularly marked in patients with a history of EVD before transplantation and during the first year after the introduction of everolimus.
Our observations suggest a link between everolimus and the risk of MVTE in renal transplant patients on everolimus, especially those with a personal history of EVD.
Further studies are needed to confirm these findings and guide clinical practice.”
Title: Venous Thromboembolism in Patients Treated with Everolimus: Insights from a Case Series and the French Pharmacovigilance Database
Authors: Audrey Delarue, Nicolas Gendron, Agnès Lillo-Le-Louet, Guillaume Goudot, Stephane Roueff, Helene Lazareth, Eric Thervet, Emmanuel Messas, Tristan Mirault, Lina Khider
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 23, 2026, 06:07Hoori Shahwar: Cerebral Venous Sinus Thrombosis Diagnosis and Management
-
Sep 23, 2026, 06:06Advancing Hemophilia Care and Patient Advocacy in Bangladesh – World Federation of Hemophilia
-
Sep 23, 2026, 05:54Bringing the Global Thrombosis and Haemostasis Community Together in 2027 – ISTH
-
Sep 23, 2026, 04:34David Akande: When Sickle Cell Crises Have No Clear Trigger
-
Sep 23, 2026, 04:13Jean Connors: Safety of Heparin Re-Exposure in Patients with Remote HIT
-
Sep 23, 2026, 04:09Beth Psaila: Applications Now Open for the Gordon Research Conference on Megakaryocytes and Platelets
-
Sep 23, 2026, 03:27Abbie Newton: How Better Data Can Reduce Platelet Wastage
-
Sep 23, 2026, 03:01Suvro Sankha Datta: Rapid Blood Group Genotyping Using Gold Oligo Nanonet Assembly
-
Sep 23, 2026, 02:55Asghar Muhammad: Exploring New Ways to Expand Blood Transfusion Compatibility